Cyclosporine
Unchecked
Cyclosporine (ciclosporin)
Sandimmune, Neoral (modified microemulsion, increased bioavailability), Gengraf, Restasis (ophthalmic)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Solid organ transplant rejection prevention0, Bone marrow transplant GVHD prophylaxis0, Severe psoriasis (short-term rescue)0, Refractory rheumatoid arthritis0, Dry eye disease (ophthalmic emulsion)0
Pharmacy
Starting dose
Transplant: 5-10 mg/kg/d divided BID, titrated to trough levels (typically 100-300 ng/mL depending on regimen and post-transplant interval); ophthalmic Restasis 0.05% one drop BID
Preparations
Sandimmune 25, 100 mg capsules; Neoral 25, 100 mg modified soft gel; 100 mg/mL oral solution; 50 mg/mL IV; Restasis 0.05% ophthalmic emulsion
US FDA Max
Transplant: regimen-specific
Pharmacology
Routes
Oral, IV, ophthalmic
Onset
Days for immunosuppressive effect
Duration
Dosing-frequency dependent
Half-life
~8-27 hours (highly variable across the population)[1]
Bioavailability
Sandimmune: highly variable (~30%); Neoral microemulsion: ~50%, less variable; Sandimmune and Neoral are NOT bioequivalent and not interchangeable[1]
Pregnancy
Used in transplant pregnancy when continued immunosuppression is required; reassuring data overall but careful monitoring needed.[citation needed]
Legal status
Purported mechanism
Cyclosporine binds cyclophilin to form a complex that inhibits calcineurin, blocking the calcium-dependent phosphatase activation of NFAT and downstream IL-2 transcription; the net effect is selective inhibition of T-cell activation.0 CYP3A4 substrate with extensive drug-interaction profile (azoles, macrolides, calcium channel blockers, grapefruit) and P-glycoprotein inhibition affecting digoxin, statins, and others. Therapeutic drug monitoring is universal — trough levels (or AUC) define safe efficacy windows[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Neoral (cyclosporine, USP) MODIFIED, Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050715s039,050716s041lbl.pdf